1834 Investment Advisors’s CRISPR Therapeutics CRSP Stock Holding History

1834 Investment Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-200	Closed	-$12K	–	247
2022 Q2	$12K	Hold	200	–	–	﹤0.01%	366
2022 Q1	$13K	Hold	200	–	–	﹤0.01%	335
2021 Q4	$15K	Hold	200	–	–	﹤0.01%	349
2021 Q3	$22K	Hold	200	–	–	﹤0.01%	333
2021 Q2	$32K	Hold	200	–	–	﹤0.01%	307
2021 Q1	$24K	Hold	200	–	–	﹤0.01%	310
2020 Q4	$31K	Hold	200	–	–	﹤0.01%	290
2020 Q3	$17K	Hold	200	–	–	﹤0.01%	312
2020 Q2	$15K	Hold	200	–	–	﹤0.01%	302
2020 Q1	$8K	Hold	200	–	–	﹤0.01%	336
2019 Q4	$12K	Hold	200	–	–	﹤0.01%	364
2019 Q3	$8K	Hold	200	–	–	﹤0.01%	397
2019 Q2	$9K	Hold	200	–	–	﹤0.01%	377
2019 Q1	$7K	Buy	+200	New	+$6.92K	﹤0.01%	365

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

1834 Investment Advisors's CRSP Position: Q3 2022 in Review

1834 Investment Advisors sold out of CRISPR Therapeutics (CRSP) in Q3 2022, closing a stake of 200 shares — an estimated $12K sold.

1834 Investment Advisors first reported a position in CRSP in Q1 2019 and held it in 14 quarters. The position peaked at $32K in Q2 2021. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

1834 Investment Advisors reported no remaining CRISPR Therapeutics position as of Q3 2022 after selling out during the quarter.
1834 Investment Advisors sold 200 CRISPR Therapeutics shares in Q3 2022, an estimated $12K.
1834 Investment Advisors first reported a position in CRISPR Therapeutics in Q1 2019 and held it in 14 quarters.
1834 Investment Advisors's CRISPR Therapeutics position peaked at $32K in Q2 2021.
436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on 1834 Investment Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.